Rocket Pharmaceuticals
RCKT
107 hedge funds and large institutions have $744M invested in Rocket Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 28 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
31% more call options, than puts
Call options by funds: $430K | Put options by funds: $327K
2.49% more ownership
Funds ownership: 94.38% → 96.87% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 120 → 107 (-13)
37% less capital invested
Capital invested by funds: $1.18B → $744M (-$432M)
46% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$17.5M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$17M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$9.76M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.31M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$9.65M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$8.06M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.45M |
| 4 |
Morgan Stanley
New York
|
-$5.53M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.32M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
ProShare Advisors
Bethesda,
Maryland
| – | -$340K | -14,924 | Closed |
|
127
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$246K | -10,826 | Closed |
|
|
AC
128
Athanor Capital
New York
| – | -$246K | -10,801 | Closed |
|
129
UBS AM
Chicago,
Illinois
| – | -$214K | -9,414 | Closed |
|
130
Marshall Wace
London,
United Kingdom
| – | -$88K | -3,877 | Closed |
|
|
PHK
131
Point72 Hong Kong
Hong Kong
| – | -$19K | -847 | Closed |
|
132
Group One Trading
Chicago,
Illinois
| – | -$11K | -501 | Closed |
|
|
PCM
133
Prelude Capital Management
New York
| – | -$4K | -184 | Closed |
|
|
TCWM
134
Total Clarity Wealth Management
St. Charles,
Illinois
| – | -$1K | -25 | Closed |
|
135
Osaic Holdings
Scottsdale,
Arizona
| – | +$614 | +31 | New |
|
RCKT Hedge Fund Activity: Q1 2020 in Review
107 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2020, worth a combined $744M — down 37% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of RCKT and 15 opened new positions — a net loss of 13 holders — while 28 trimmed existing stakes and 43 added.
The largest buyer was Westfield Capital Management, adding an estimated $17.5M. The largest seller was Deerfield Management, cutting an estimated $9.65M.
- 107 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2020, down from 120 in Q4 2019.
- Funds reported $744M of Rocket Pharmaceuticals stock for Q1 2020, down 37% quarter-over-quarter.
- 15 funds opened new Rocket Pharmaceuticals positions in Q1 2020 and 28 closed out, a net change of -13 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2020 was Westfield Capital Management, an estimated $17.5M added.
- The largest Rocket Pharmaceuticals seller in Q1 2020 was Deerfield Management, an estimated $9.65M sold.
Based on aggregated 13F filings for Q1 2020.